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ABSTRACT
Myc (c-Myc) counteracts p27 effects, and low p27 usually correlates with high Myc 
expression in human cancer. However there is no information on the co-expression 
of both genes in chronic lymphocytic leukemia (CLL). We found a lack of correlation 
between RNA and protein levels of p27 and Myc in CLL cells, so we determined the 
protein levels by immunoblot in 107 cases of CLL. We observed a high p27 protein 
expression in CLL compared to normal B cells. Ectopic p27 expression in a CLL-derived 
cell line resulted in cell death resistance. Surprisingly, Myc expression was very low 
or undetectable in most CLL cases analyzed, with a clear correlation between high 
p27 and low Myc protein levels. This was associated with low Skp2 expression, which 
is consistent with the Skp2 role in p27 degradation and with SKP2 being a Myc target 
gene. High Myc expression did not correlate with leukemia progression, despite 
that cell cycle-related Myc target genes were upregulated. However, biochemical 
analysis showed that the high p27 levels inhibited cyclin-Cdk complexes even in Myc 
expressing CLL cells. Our data suggest that the combination of high p27 and low Myc 
is a marker of CLL cells which is mediated by Skp2.
INTRODUCTION
Chronic lymphocytic leukemia (CLL) is the most 
common leukemia in the Western countries and it is 
characterized by the progressive accumulation of clonal 
B lymphocytes in peripheral blood bone marrow and 
lymph nodes [1-3]. CLL is a heterogeneous disease with 
variable clinical presentation and evolution. Some patients 
have an indolent course with long survival without need 
for treatment while others experience an aggressive 
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disease. Patients with no mutation in the variable region of 
the immunoglobulin genes (IGH) or with high expression 
of CD38 or ZAP70 had an aggressive course, whereas 
patients with mutated IGH clones or low expression 
of CD38 or ZAP70 cells usually show an indolent 
course [1, 3].
It has been reported alterations of cell cycle 
regulatory molecules in CLL, such as cyclin E, cyclin D, 
cyclin-dependent kinase (Cdk) 4 and Cdk2 [4, 5]. The 
Cdk inhibitor p27KIP1 (p27), that negatively controls 
cell-cycle progression, has been observed overexpressed 
in CLL cells [6-8]. This is in contrast to the majority 
of human tumors, where low levels of p27 are found 
[9-11]. p27 down-regulation in cancer has been associated 
with its function as an inhibitor of cell cycle. Indeed, a 
marked reduction in the abundance of p27 is common in 
many human tumors. In most cases where p27 regulation 
is described, the levels of p27 are mainly regulated at 
posttranslational level. This is mostly carried out by the 
SCFSkp2 ubiquitin ligase complex, where Skp2 acts as the 
p27-recogninzing subunit [12-14].
c-Myc (Myc herein after) is an oncogenic 
transcription factor or the helix-loop-helix/leucine zipper 
protein family. Myc forms dimers with the protein Max. 
These heterodimers bind to specific sequences called 
E-boxes in regulatory regions of target genes as well 
as intergenic regions. Myc-Max dimers bind to 15% of 
genomic loci and regulate about 1000 genes [15, 16]. 
Myc function integrating multiple signals, mediating 
transcriptional response that impinges on a wide array 
of biological functions such as cell cycle control, 
genomic instability, energetic metabolism, protein 
synthesis, intercellular communication and control of cell 
differentiation [17-22]. Consistent with these functions, 
high levels of this protein has been found in many 
human tumors [18, 23], and prominently in leukemia and 
lymphoma [24, 25].
In CLL, contradictory results on Myc mRNA levels 
in peripheral blood cells have been published. Some 
studies reported low Myc mRNA levels whereas high 
expression levels have been described in other [26-28]. 
MYC amplification and chromosomal rearrangements 
are very rare in CLL (less than 3%) but gains at 
8q23.3-q24.3 (where MYC maps) was identified as a poor 
prognostic marker [29]. The frequency of MYC mutation, 
amplification and translocation increase in a subset of CLL 
with aggressive disease (30% of the cases) [30, 31] and in 
the CLL transformation to high grade lymphoma known 
as Richter syndrome [30, 32-34].
In cellular models, Myc blocks p27 antiproliferative 
activity and in most tumors there is an inverse correlation 
between Myc and p27 levels. Myc abrogates p27 function 
in proliferation arrest. This antagonism occurs through 
at least three levels. First, Myc represses p27 gene 
(CDKN1B) expression [35, 36]. Second, Myc induces 
cyclins and CDKs which can sequester p27 in CDK-
Cyclin complexes [37-40]. Third, Myc induces the 
transcription of Skp2 [41]. The F-box protein Skp2 is the 
p27-recognizing subunit and the major responsible for p27 
ubiquitination and degradation [42-44].
Despite their functional interactions, it is unknown 
whether Myc and p27 are coexpressed in CLL and whether 
Myc can compensate the reported high p27 expression. 
Here we studied the regulation of p27 and Myc in tumoral 
peripheral CLL cells and their correlation with the clinical 
features of the leukemia. In a cohort of more than 100 
patients we analysed protein and mRNA expression of 
p27 and Myc. We found that p27 and Myc levels were 
inversely correlated, being p27 overexpressed and Myc 
downregulated. This correlation appears inverted in CLL 
with respect to conversely to most tumors. The excess 
in p27 counteracts Myc effect on cell cycle in the small 
number of samples with high Myc expression. We also 
found that low p27 and high Myc expression correlated 
with Skp2 suggesting a mechanistic explanation for 
Myc and p27 inverse correlation in CLL. Moreover, the 
enforced expression of p27 in a CLL-derived cell line 
resulted in resistance to apoptosis.
RESULTS
High p27 protein expression in CLL
We first studied the mRNA levels of p27 in a cohort 
of 67 CLL patients by RT-qPCR or Northern blot analysis 
(Supplementary Table S1). The results revealed an increase 
(~5 fold as a mean) in p27 mRNA in CLL samples, as 
compared to controls (tonsil and peripheral blood B 
lymphocytes) (Figure 1A) The analysis of the mRNA data 
loaded in the Oncomine databank (www.oncomine.org) 
revealed a high heterogeneity among different studies. In 
some studies CLL samples showed higher levels of p27 
mRNA with respect to controls, whereas these differences 
were not observed in other studies. Supplementary 
Figure S1 show two discordant studies. As previous 
results from our lab and others demonstrated an intense 
post-transcriptional regulation of p27 in human leukemia 
cells [45], we compared p27 mRNA (by RT-qPCR) and 
p27 protein (by immunoblot) levels in a subset of CLL 
cases. We confirmed the lack of correlation between 
both mRNA and protein levels in some samples (Figure 
1B). In view of this result we decided to analyse p27 at 
the protein level in peripheral blood cells from 107 CLL 
cases by immunoblot. p27 signals were quantified by 
densitometry analysis and normalized against actin levels 
of each sample. The results showed that p27 protein is 
clearly overexpressed in CLL cells compared to normal 
B cells (86% of samples) (Figure 1C). A representative 
immunoblot showing p27 protein expression is shown 
in the Figure 1D. CLL cells showed a mean of 3-fold 
higher levels of p27 than controls. Only a minority of 
CLL samples showed levels of p27 protein similar to those 
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Figure 1: p27 expression in CLL samples. (A) p27 mRNA expression in CLL cells and in healthy B-cells determined by RT-qPCR. 
(B) Comparison of p27 mRNA expression (determined by RT-qPCR) and p27 protein expression (determined by immunoblot) in the same 
CLL samples. The black bars show the densitometric quantification of p27 protein levels normalized to actin expression. (C) p27 protein 
expression in CLL cells and in healthy B-cells (controls). (D) A representative immunoblot showing p27 and actin expression. The arrows 
mark examples of CLL patient samples with low p27 expression. T, tonsils. (E) Immnofluorescence analysis showing nuclear p27 in CLL 
cells from four patients. Nuclei are stained with DAPI.
observed in healthy control B cells. The high p27 levels in 
CLL cells is a striking finding because of the well-known 
role of p27 as inhibitor of the cell cycle progression. It 
is also in contrast to the situation in the rest of human 
tumors, where p27 is down-regulated, However, high 
p27 levels have been described in some tumors (breast, 
colon, melanoma, ovary, thyroid and lymphomas) where 
an aberrant cytoplasmic expression of p27 was observed 
[46-48]. Thus we explored the possibility of a 
p27 cytoplasmic localization in CLL cells. The 
immunofluorescence analysis revealed that p27 localization 
was mainly nuclear in the 9 fresh CLL samples analyzed. 
Some representative cases are shown in Figure 1E.
We next asked for a possible correlation of p27 
protein expression and some CLL prognostic markers. 
We found that low p27 was associated to high ZAP70 
expression and absence of 13q14 deletion (Supplementary 
Figure S2). No significant correlation was found in the 
Oncotarget4697www.impactjournals.com/oncotarget
others markers tested (expression of CD38, p53 deletion 
and ATM deletion), Furthermore we did not detect in our 
cohort of CLL patients a significant association of high 
p27 with Rai staging (P = 0.88, n = 85), progression of the 
leukemia (P = 0.69, n = 86) and with overall survival (P = 
0.4, n = 86) (not shown).
Low Myc protein expression in CLL
In view of the involvement of Myc in B-cell 
malignancies and the Myc-p27 functional antagonism 
described in most models, we set out to examine Myc 
expression in our CLL cases (Supplementary Table S1). 
Myc mRNA levels were clearly down-regulated in CLL 
samples (n = 83) with respect to controls (Figure 2A). 
The Myc mRNA data loaded in the Oncomine databank 
(www.oncomine.org) revealed also contradictory results 
(two discordant studies are shown in Supplemental 
Figure S3). Our analysis revealed a poor correlation 
between Myc mRNA and protein levels (P = 0.39, n = 31) 
(Figure 2B). We analyzed Myc protein levels in 102 
CLL samples by immunoblot and the Myc protein levels 
were quantified by densitometry and normalized against 
the actin levels. Most of patients showed undetectable 
or low levels of Myc protein, as compared to controls 
(Figure 2C, D). Only 18.6% of our samples (19 samples) 
showed a Myc expression higher than in control samples. 
It is noteworthy that only five patients (5% of cases) 
showed Myc levels ≥2-fold above control level. This low 
number of Myc-positive specimens makes it difficult to 
generate statistically significant data. However, we did not 
found any correlation between Myc expression and any 
of the bad prognosis markers analyzed (CD38 or ZAP70 
expression, trisomy 12, ATM deletion, p53 deletion and 
13q14 deletion). We also failed to detect a close correlation 
between high Myc protein levels and NOTCH mutation 
Figure 2: Myc expression in CLL cells. (A) Myc mRNA expression in CLL cells and in healthy B-cells determined by RT-qPCR. 
(B) Comparison of Myc mRNA expression (determined by RT-qPCR) and p27 protein expression (determined by immunoblot) in the same 
CLL samples. The black bars show the densitometric quantification of Myc protein levels normalized to actin expression. (C) Myc protein 
expression in CLL cells and in healthy B-cells (controls). (D) Representative immunoblot showing Myc and actin expression. T, tonsils
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or overexpression (not shown). We did not detect a 
significant difference in the overall survival between Myc 
protein overexpressors and the rest of patients (P = 0.10, 
n = 82). Moreover we did not detect a significant impact 
of Myc protein levels on the progression of the disease 
(P = 0.15, n = 83). The main clinical characteristics of the 
patients with high Myc expression are summarized in the 
Supplementary Table S2.
We next studied the expression of Myc and p27 in 
the same samples to explore the correlation between the 
Myc and p27 levels in CLL cells in a cohort of 102 CLL 
cases. Immunoblot studies revealed an inverse pattern 
of expression between p27 and Myc (Figure 3A shows 
a representative blot). The majority of the samples with 
low p27 expression showed high Myc levels (Figure 3B). 
The densitometric analysis of MYC signals in the blots 
revealed that most of the patients with low Myc expression 
(96%) showed high p27 expression (Figure 3B). Although 
it there was not a linear correlation between the levels 
of the two proteins, the Spearman’s coefficient showed 
that Myc and p27 levels showed an inverse correlation 
(Spearman’s Rho = – 0.2047, P = 0.03, not shown).
Lymph nodes from CLL patients (n = 124) were 
also analyzed for the expression of p27 and Myc by 
immunohistochemistry. A marked nuclear p27 signal 
was observed in the non-proliferative center area of the 
node in all cases (representative micrographs are shown 
in Supplementary Figure S4). Myc was only expressed 
in the proliferative centers in a subset of nodes. Only 
16% of the nodes showed expression of Myc in the 10% 
or more of the cells. Similarly to peripheral blood cells, 
there was no correlation between high Myc expression 
and Rai stage or disease progression (i.e., requiring 
treatment).
p27 induces Myc downregulation and protects 
from apoptosis in CLL-derived cells
To further investigate the mechanisms that could 
explain the striking expression pattern of Myc and p27 in 
CLL and their functional effects, we over-expressed p27 
in the MEC1 cell line, a cell line derived from CLL cells. 
A p27 expression vector was transiently transfected into 
MEC1 cells, resulting in a dramatic increase in p27 levels 
with respect to empty vector-transfected cells (Figure 4A). 
Unlike peripheral blood CLL cells, proliferating MEC1 
cells expressed high levels of Myc, but Myc expression 
was blunted by the over-expression of p27 (Figure 4A). 
We next tested the cell cycle profile of these p27-
transfected cells to assess their functionality. As expected, 
Figure 3: p27 and Myc coexpression in CLL cells. (A) Representative immunoblot showing p27, Myc and actin expression in cells 
from CLL patients and from tonsil cells (T, tonsils). (B) Expression levels of Myc and p27 in CLL patients. The protein levels of p27 and 
Myc as determined by film densitometry and normalized to actin, were classified in three categories with respect to the mean of expression 
in controls. (C) Classification of patients with low and high Myc protein expression according to their p27 levels.
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p27-transfected cells were arrested in G0/G1 (Figure 4B). 
These results are consistent with the observations in 
vivo, where the majority of peripheral blood CLL cells 
are arrested in G0/G1, and high levels of p27 and low 
levels of Myc were observed. The gradual accumulation 
of immunologically dysfunctional B lymphocytes (most of 
them in G0 phase of the cell cycle) observed in CLL has 
been ascribed to defective apoptosis [49-51]. Therefore 
we explored whether p27 over-expression may also play a 
role in the resistance to apoptosis, a typical characteristic 
of CLL cells. For this purpose we generated a p27-YFP 
construct and transfected it into MEC1. As apoptotic 
stimulus we chose fludarabine, a drug commonly used 
in CLL treatment [52, 53] and which induces a decrease 
in p27 expression in CLL-derived cells in culture [5]. 
Apoptosis was determined after treatment of MEC1 
cells transfected with the p27 expression vector with 
fludarabine. MEC1 cells with high p27 levels were more 
resistant to fludarabine-induced cell death than control 
cells as assessed by cell viability analysis using trypan 
blue (Figure 4C). We also measured the apoptosis in 
MEC1 p27-expressing cells by annexin V-binding by flow 
cytometry. The results showed that p27-expressing cells 
were more resistant to apoptosis (Figure 4D). The same 
result was observed by analyzing the expression of active 
caspase 3 (Figure 4E). Altogether these results show that 
p27 confers apoptosis resistance in MEC1 cells suggesting 
that the high p27 levels in CLL cells may contribute to 
the accumulation of leukemic cells. Overexpression of the 
anti-apoptotic protein Blc2 is a hallmark of CLL [54, 55] 
and therefore it may be expected a correlation between 
the p27 and Bcl2 levels in the CLL. We analyzed by 
immunoblot the expression of Bcl2 in our cohort of CLL 
samples and we found a direct correlation between Bcl2 
and p27, showing that samples with low p27 expression 
also have low Bcl2 protein levels (Figure 4F).
Figure 4: p27 and Myc are mutually regulated in MEC1 cells. (A) Immunoblot showing p27 and Myc expression in MEC1 
cell line transfected with a p27 expression vector (pCEFL-p27) and the corresponding empty vector. Proteins were analyzed 24 h after 
transfection. Actin levels are shown to asses protein loading. (B) MEC1 cells were transfected with pEYFPp27 vector and 24 h later the cell 
cycle of transfected cells was analysed by flow cytometry. The empty vector (pEYFP) was used as controls. The percentage of cells in the 
G0/G1 phase is indicated. (C) p27 expression rescued fludarabine-induced cell death. Cells were transfected with pEYFPp27 and pEYFP 
vector and 24 h after transfection the cells were treated with 10 μM fludarabine and cell death was determined 24 h later by trypan blue 
exclusion assay. (D) MEC1 cells were transfected and treated as in C, and the apoptosis was determined by annexin V binding, assessed by 
flow cytometry. (E) MEC1 cells were transfected and treated as in C and the levels of active caspase 3 were determined by immunoblot. 
(F) Correlation of high expression of p27 protein with higher Bcl2 levels in CLL cells.
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Cyclins and Skp2 regulation in Myc-expressing 
CLL cells
Given the role of Myc as an oncoprotein, the 
low Myc expression in most CLL cells was intriguing. 
We explored the possibility that perhaps Myc was not 
functional in these CLL cells. As Myc function as a 
heterodimer with the protein Max, we first asked for 
the expression of Max in our CLL samples. We showed 
that Max mRNA and protein were present in all samples 
analyzed (n = 78 and 26, respectively) and, interestingly, 
Max mRNA (Supplementary Figure S5A) and Max 
protein expression was higher in CLL than in controls 
(Supplementary Figure S5B). We next asked for the 
functionality of Myc in CLL cells expressing Myc. We 
first analyzed the expression of cyclins A and E, which 
are cell cycle regulators known to be induced by Myc 
[17, 18]. We selected three CLL cases with high and six 
with low Myc levels and the results clearly showed that 
in the cells with high Myc levels, protein expression of 
cyclin A and E were also higher (Figure 5A). Indeed, there 
was a clear correlation between Myc and cyclin A levels 
(Figure 5B).These results suggested that Myc is functional 
in CLL cells. Thus we next asked whether in CLL cells 
expressing both p27 and Myc, p27 was also functional, 
and can bind to and inhibit Cdk-cyclin complexes. Two 
approaches were used. First, the total lysate of B cells 
from two CLL cases expressing p27, one with high Myc 
levels and the other with low Myc levels (Figure 5C) were 
chromatographed through a gel filtration column on a 
FPLC apparatus. The results showed that in the presence of 
Myc there was a displacement of p27 from free forms into 
high-molecular weight fractions containing cyclins and 
Cdks complexes (Figure 5D), suggesting the formation 
of p27-Cdk-Cyclin complexes and thus the inhibition of 
Cdk2. To confirm the presence of these complexes we 
performed immunoprecipitations with anti-Cdk2 antibody 
and the results showed that p27 was bound to Cdk in 
Myc-expressing CLL cells (Figure 5E, upper panel). The 
previous results strongly suggested that p27 was inhibiting 
Cdk2 in CLL cells. To support this hypothesis, we directly 
determined Cdk2 activity in CLL lysates expressing both 
Myc and p27, as well as the ability of these lysates to 
inhibit Cdk2. First, we immunoprecipitated Cdk2 and its 
kinase activity was assayed by determining the level of 
phosphorylation at threonine 187 of recombinant inactive 
p27. The results show that the p27 present in the CLL cells 
was able to inhibit the endogenous Cdk activity, regardless 
the expression level of Myc (Figure 5E, lower panel). In 
a second approach we asked whether the p27 present in 
the CLL cells was able to inhibit exogenous Cdk2, using 
MEC1 extracts as the source of active Cdk2. This was 
performed in two ways. First we showed that lysates from 
p27-expressing CLL cells inhibited the Cdk2 purified 
by immunoprecipitation from MEC1 cells (Figure 5F). 
Second, we mixed lysates from MEC1 and two CLLs 
(with p27), and we showed that the immunoprecipitated 
Cdk2 from this mixtures was inactive, whereas the Cdk2 
from MEC1 lysates was active (Figure 5G). This result is 
in line with the proposal that p27 overrides the effects of 
Myc as cell cycle stimulator, and are in line with the lack 
of a clear correlation between high Myc expression and 
progression of the leukemia. We conclude that, although 
Myc induces S-phase cyclins in CLL cells where it is 
expressed, the high p27 levels bind to most cyclin-Cdk 
complexes formed. Thus, the results suggest that the p27 
present in the Myc-expressing cells would impair cell 
cycle progression.
Figure 5: Expression of cell cycle regulators and cyclin-Cdk-p27 complexes in CLL cells. (A) Representative immunoblot 
showing the levels of cyclins A and E in CLL cells with and without Myc/p27. Actin levels were also determined to assess protein loading.
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We were intrigued by the inverse correlation 
between Myc and p27 in CLL, which follows the 
opposite pattern than in most tumors. Samples with 
high levels of Myc (11%) (Figure 3B) show lower p27 
levels, suggesting a mechanistic connection between the 
expression of both proteins. To explore this mechanism 
found in CLL we studied Skp2 expression. Skp2 is 
the main protein involved in p27 degradation and we 
previously reported that SKP2 is a Myc-target gene [41]. 
Thus, we determined Skp2 protein expression, along with 
p27 and Myc, in our CLL cohort. The immunoblot results 
showed that high Skp2 levels correlated with high Myc 
and low p27 in almost all analyzed cases (a representative 
blot is shown in Figure 6A). In the samples with low 
Skp2 expression the mean levels of p27 protein were 
significantly higher (Figure 6B) whereas the mean levels 
of Myc protein were significantly higher in samples with 
high Skp2 (Figure 6C). The results argue for a pathway 
Myc-Skp2-p27 to explain the inverse correlation of Myc 
and p27 in CLL.
Figure 5: (B) Correlation between Myc and cyclin A protein levels in CLL cells. (C) Immunoblot showing Myc and p27 protein 
levels in four patient’s cells selected for the experiments shown in D. (D) Molecular filtration chromatographic separation of 
CLL protein extracts followed by immunoblot for cyclins A, E and Cdk2. The elution of the 55 and 30 kDa proteins is shown 
at the top. (E) Immunoblot (IB) showing the levels of Myc and p27 in three CLL samples and MEC1 cells and kinase assay of 
Cdk2 in the same extracts. Proteins were immunoprecipitated with anti Cdk2 and the presence of both cyclin E, p27 and Cdk2 
were determined by immunoblot. Lower panel: kinase assays were performed using HisCK- as kinase substrate. M, mock 
kinase reaction without extract. (F) Immunoprecipitation of Cdk2 and kinase assay of the immunoprecipitates of MEC1 cells 
and MEC1 cells incubated with lysates from a CLL sample (#01). (G) Immunoprecipitation of Cdk2 and kinase assay from 
MEC1 cells and from mixed lysates prepared with MEC1 cells and two CLL samples (#01 and #10).
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DISCUSSION
It has been reported that expression of p27 has 
both prognostic and therapeutic implications in several 
tumors [9-11]. In sharp contrast to the scenery found in 
most or all human tumors including other leukemia we 
have found in CLL a high p27 expression and low Myc 
expression. We also found that p27 mRNA levels did not 
always correlate with p27 protein, which is in line with 
previous studies describing the intense posttranscriptional 
[8, 56, 57] and posttranslational regulation of p27 [10, 45, 
58]. This argues against the relevance of mRNA-based 
studies. Therefore, we determined the p27 levels in 107 
CLL samples by immunoblot and signal densitometry. 
The results showed a high p27 protein expression by 
immunoblot in a majority the CLL cases. These results 
agree with previous studies [6-8]. However, in contrast to 
previous reports [5], p27 was predominantly nuclear in 
our samples. High p27 expression has been reported to 
mark rapid progression of the disease [7] but we could 
not confirm these results in full as we we only observe 
a correlation between cases with ZAP70 expression and 
absence of 13q14 deletion with low p27 expression.
Why is p27 so highly expressed in CLL, despite 
the well-known activity of p27 as inhibitor of cell cycle 
progression? It is accepted that inherent defects in 
cell death of CLL lymphocytes are responsible for the 
accumulation of leukemic cells, the majority of them are 
arrested in G0 phase of the cell cycle [3, 49]. G0 arrest 
is consistent with the Cdk inhibition brought about by 
p27, particularly Cdk2. We hypothesize that p27 could 
contribute to the resistance to cell death of CLL cells, 
either as a consequence of the cell cycle arrest or through 
other less defined mechanisms. To explore this hypothesis 
we generated and transfected p27 expression vectors 
into the CLL-derived MEC1 cells, and we found that 
p27 overexpression resulted in resistance to apoptosis. 
The correlation beween high p27 and low apoptosis was 
also consistent by the correlation between p27 and Bcl2 
expression that we found in CLL patients.
Myc is upregulated in leukemia and lymphoma 
[25] and Myc counteracts the p27-mediated inhibition of 
proliferation in many models. However, the correlation 
between Myc and p27 in CLL cells has never been 
analyzed. Previous studies have reported controversial 
data so as Myc mRNA expression in peripheral blood 
CLL cells [26-28, 59-61]. However, Myc protein stability 
is also under intense postransductional regulation [62-64] 
and, as in the case of p27, mRNA-base studies can offer 
misleading information so as the levels of Myc protein in 
Figure 6: Overexpression of Skp2 in Myc-expressing CLL cells. (A) Representative immunoblot showing the protein levels of 
Myc, p27 and Skp2 in CLL cells. Actin levels are also shown as protein loading control. (B) p27 protein levels in CLL cells with high or 
low expression of Skp2. (C) Myc protein levels in CLL cells with high or low expression of Skp2.
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CLL cells. Therefore we studied the Myc protein levels by 
immunoblot. The results showed a very low expression 
of Myc protein in CLL cells. Actually, in a 49% of our 
CLL samples, Myc was under our level of detection by 
immunoblot. Moreover in most of our patients classified as 
“Myc positive”, Myc levels were not higher than in normal 
tonsil B-cells. We observed the opposite correlation in 
CLL, i.e., high p27 and low Myc in the peripheral blood 
CLL lymphocytes of most patients (78%) whereas only 
45% of the patients with p27 expressed Myc above the 
level detectable in our immunoblots. The low Myc and 
high p27 expression that we observed in a majority of 
CLL cases is the opposite pattern observed in most human 
tumors. It is noteworthy that in the small subset of CLL 
samples with high Myc expression we did not detect a 
significantly faster disease progression, despite that those 
cells show molecular hallmarks of Myc-transformed cells, 
i.e., high levels of cyclins A and E. Furthermore, in these 
Myc-expressing cells, p27 was found in complexes with 
Cdk-cyclins and Cdk2 kinase activity was efficiently 
inhibited. We hypothesize that in those cases with 
concomitant p27 and Myc expression, p27 overrides the 
activity of Myc-as cell cycle stimulator. The hypothesis 
is in line with the lack of a clear correlation between high 
Myc expression and progression of the leukemia.
We explored whether there is a mechanistic link 
between the low Myc and high p27 expression in CLL. 
Our results show very low levels of Skp2 in the majority 
of CLL cases, in correlation with low p27. Moreover, Skp2 
mRNA and protein levels were elevated in those cases with 
high Myc expression. This is in full agreement with SKP2 
being a Myc target gene which expression in proliferating 
cells depends on Myc [41]. As Skp2 is a subunit of the 
SCFSKP2 complex that promotes p27 degradation [12, 13], 
Skp2 levels could explain the inverse correlation between 
Myc and p27 in CLL. Therefore, we suggest that in CLL 
cells Myc induces p27 degradation through up-regulation 
of Skp2 mRNA in CLL cells. Altogether, the results offer 
an explanation for the striking Myc and p27 expression 
pattern found in CLL. Further work is necessary to 
dissect out the contribution of the Myc-p27 axis to CLL 
pathogenesis and their use as markers of the disease.
MATERIAL AND METHODS
Patient samples and progression criteria
Peripheral blood lymphocytes from 159 CLL 
patients were studied at the mRNA level, protein level 
or both (Supplementary Table S1). CLL samples were 
obtained from the Hospital Universitario Marqués 
de Valdecilla of Santander (138 samples), Hospital 
Universitario Dr Negrín of Las Palmas (28 samples) 
and from Hospital Clínic of Barcelona (10 samples). 
Written informed consent in accordance with the Ethics 
Committee of each hospital and the Declaration of 
Helsinki were obtained. The biological characteristics 
of the patients (age, sex, clinical stage according to Rai 
classification, cytogenetic alterations, treatment and 
number of samples analyzed for RNA and protein) or 
11q14) are summarized in Supplementary Table S1. 
Control samples were obtained from healthy donors 
(peripheral blood lymphocytes) and from tonsillectomy of 
patients with tonsillitis (tonsils). CLL cells were isolated 
by Ficoll-Paque or flow cytometry using anti CD19. Most 
of patients (60 %) were diagnosed in an early stage of the 
disease (stages 0 and I). 43 % of patients progressed, most 
of these (81%) required treatment. Progressive disease 
was considered when at least one of the following criteria 
was present: a) evidence of progressive marrow failure 
manifested by the development anemia (Hb <10g/dL) and/
or thrombocytopenia (<100x109/L); b) massive (i.e., at 
least 6 cm below the left costal margin) or progressive or 
symptomatic splenomegaly; c) massive nodes (i.e., at least 
10 cm in longest diameter) or progressive or symptomatic 
lymphadenopathy; d) progressive clonal lymphocytosis 
with an increase of more than 50% over a 2-month period 
or lymphocyte doubling time of less than 6 months.; e) 
autoimmune cytopenia that is poorly responsive to 
standard therapy; f) constitutional symptoms. 124 lymph 
nodes of CLL with ganglionar affectation were also 
included in the study. Samples were obtained from the 
Biobank of the IDIVAL-Hospital Universitario Marques 
de Valdecilla. 16 samples of non-metastatic nodes in 
surgical specimens were used as controls.
Analysis of leukemia markers
The percentage of tumoral cells (CD19+, CD5+) 
as well as the expression levels of ZAP70 and CD38 
was analyzed by flow cytometry as follow. A hundred 
microliters of whole peripheral blood in EDTA were 
incubated with CD38-FITC (Citognos), CD19-PERP-Cy5, 
CD20-APC and CD5-PE-FITC (antibodies from Becton-
Dickinson) to identify surface membrane antigens. Then 
cells were fixed and permeabilized using the Fix & Perm 
kit (Caltag Laboratories, Burlingame, CA) and incubated 
with the ZAP70 monoclonal antibody (R-phycoerythrin 
conjugated; clone 1E 7.2, Caltag Laboratories). After, 
cells were analyzed by flow cytometry (BD FACSCanto, 
Becton Dickinson Immunocytometry Systems, San Jose, 
CA). ZAP70 results were expressed as the percentage of 
CD5/CD19 positive cells compared to T cells (cut-off 
20%). CD38 expression was defined as positive when 
identified in more than or equal to 30% of the gated CD19/
CD5 positive cells. Cytogenetic alterations were assessed 
by fluorescence in situ hybridization (FISH) using the 
FISH LLC Multicolor Kit (LSI D13S319-13q14)/13q34/
CEP12, LSI p53/LSI ATM) (Vysis-Abbott Molecular, 
USA) At least 100 intact, non-overlapping nuclei were 
analyzed. Control values were previously established 
based on samples of 10 controls X±3SD (mean plus three 
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standard deviations). The cut-offs value for p53, 13q14 or 
ATM deletion was 10%, and for trisomy 12 was 3%.
Cell culture and transfection
MEC1 cells (DSMZ-497), derive from human 
CLL in prolymphocytic transformation [65], were grown 
in RPMI 1640 medium supplemented with 10% fetal 
calf serum and antibiotics at 37ºC and 5% CO2. MEC1 
were transiently transfected by nucleofection (Amaxa 
electroporator) with pCEFL-p27, pEYFP-p27, pRS-shMyc 
or the corresponding empty vector. A green fluorescent 
protein vector (pmaxGFP, Amaxa) was co-transfected to 
assess transfection efficiency. pEYFP-p27 was constructed 
by inserting the human p27 cDNA into the BamHI and 
XbaI restriction sites of pEYFP-C1 vector (Clontech). 
A hemocytometer was used to count the concentration 
of cells. Dye exclusion method was used for assessment 
of cell viability. Trypan Blue was the vital stain used to 
selectively color dead cells. MEC1 transfected with a p27 
expression vector and with empty vector were treated with 
10 μM fludarabine (Sigma-Aldrich) for 24 hours.
RNA analysis
RNA was extracted by Trizol or RNeasy kit 
(Qiagen). First-strand cDNA was synthesized from 
1 μg of total RNA using Script reverse transcriptase 
(BioRad). Quantitative RT-PCR was performed with the 
SYBR Green PCR kit (BioRad). The expression levels 
were normalized to the expression of ribosomal protein 
RPS14 mRNA. The following primers were used: for 
Myc 5’- TCGGATTCTCTGCTCTCCTC-3’ and 5’- 
GAGCCTGCCTCTTTTCCAC3’; p27 5’- CCGGCTAAC 
TCTGAGGACAC-3’ and 5’- AGAAGAATCGTCGGT 
TGCAG-3’; RPS14: 5’- TATCACCGCCCTACACA 
TCA-3’ and 5’- GGGGTGACATCCTCAATCC-3’. The 
mean value of Myc and p27 mRNA from of 16 control 
samples (tonsils and CD19+ cells) were assigned value =1. 
mRNA levels of the CLL samples were normalized against 
this value Northern blot analysis for p27, Myc anc Max 
was performed as described previously [45, 66].
Immunoblots
CLL and MEC1 cells were lysed in lysis buffer 
(1% NP40, 0.5% SDS, 50 mM Tris-HCl pH 7.5, 
150 mM NaCl, 1 mM EDTA, 10% glycerol, 10 mM 
NaF and protease inhibitors) for 20 minutes at 4ºC. 
Lysates were cleared by centrifugation. 40 μg of 
lysates were subjected to SDS-PAGE and immunoblot 
as described previously [45]. The antibodies used 
were anti-Actin (I-19, goat polyclonal, sc-1616), 
anti-MYC (N-262, sc-764), anti-SKP2 (H-435, 
sc-7164), anti-p27 (C-19, sc-528 and sc-528-G, rabbit 
and goat polyclonal respectively) anti cyclin E (M-20, 
sc-481) or anti-cyclin E (HE12, mouse monoclonal, 
sc-247), anti-cyclin A (H-432, sc-751), or anti-CDK2 
(M2, sc-163) (unless otherwise indicated, all rabbit 
polyclonals from Santa Cruz Biotechnology), anti-p27 
monoclonal antibody (K-25020; Transduction Labs), 
and anti-Thr(P)-187-p27 (rabbit polyclonal, 71-7700; 
Invitrogen). The blots were developed with secondary 
antibodies conjugated to IRDye680 and IRDye800 
(Li-Cor Biosciences) and visualized in an Odyssey 
scanner. Immunoblots quantification and densitometry 
analysis were carried out using the ImageJ software. p27 
and Myc values were normalized to the actin protein level 
in each sample. The mean value of Myc and p27 protein 
from of 15 control samples (tonsils and CD19+ cells) were 
assigned value =1. Proteins levels of the CLL samples 
were normalized against this value
Immunoprecipitations and kinase assays
For immunoprecipitations, cells were lysed in non-
denaturing lysis buffer (50 mM Tris pH7.5, 150 mM NaCl, 
0,5% NP40, 1mM EDTA and protease inhibitor cocktail) 
and protein extracts were cleared by centrifugation. 
Protein extracts (1 mg per assay) were immunoprecipitated 
with 1 μg of anti-CDK2 (M2, Santa Cruz Biotechnology) 
and collected on protein G-Dynabeads (Invitrogen). 
After extensive washing with non-denaturing lysis 
buffer, immunocomplexes were subjected to SDS-
PAGE and immunoblot analysis as previously described. 
For kinase assays, after washing with non-denaturing 
lysis buffer, immunocomplexes were additionally 
washed in kinase buffer (50 mM Hepes-NaOH pH7.2, 
150 mM NaCl, 10 mM MgCl2, 2.5 mM EGTA, 1 mM 
EDTA, 1 mM dithiothreitol, 10% glycerol, 10 mM 
β-glycerophosphate and 10 mM NaF) and resuspended in 
kinase buffer (40 μl) supplemented with 50 μM ATP and 
0.1 μg of recombinant His6-p27CK- peptide (HisCK-), 
as described [67]. HisCK- vector was constructed by 
subcloning the cDNA into the pET28a vector (Novagen), 
and the peptide was expressed in E. coli BL21 strain upon 
IPTG induction, and purified through Ni affinity columns 
(Macherey-Nagel). The kinase reaction was incubated 
for 60 min at 30ºC and stopped by addition of Laemmli 
loading buffer to the reaction mixture. Samples were then 
heated at 95ºC for 5 min and subjected to SDS-PAGE 
and immunoblot analysis with anti-p-Thr187-p27 (rabbit 
polyclonal, 71-7700, Invitrogen) first and with anti-p27 
(Goat polyclonal, sc-528-G, Santa Cruz Biotech.) later. 
The signals were revealed with anti-rabbit and anti-
goat secondary antibodies conjugated to IRDye680 
and IRDye800, respectively (Li-Cor Biosciences). 
Immunoblots were scanned in an Odyssey scanner.
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Immunofluorescence and immunohistochemistry
Cytospin preparations were fixed with 
paraformaldehyde 3.7% in PBS for 10 minutes to room 
temperature and permeabilized with 0.2% triton X-100 
(10 minutes). Anti-p27 (C-19) and anti-Myc antibodies 
(N-262, all antibodies were rabbit polyclonals from Santa 
Cruz Biotech.) were incubated overnight, and Texas Red 
or FITC-conjugated secondary antibody (Dako) were 
used to detect the presence of p27 and Myc. Samples 
were mounted with Vectashield (Vector) containing 
4’-6-diamidino-2-phenylindole (DAPI) to stain nuclei 
and photographed under a fluorescence microscope. For 
immunohistochemistry, the CLL, sections of CLL lymph 
nodes were arrayed into a new paraffin block using a tissue 
microarray (TMA) workstation (Beecher Instruments, 
Silver Spring, MD). Immunohistochemical staining for 
Myc (Y29 rabbit polyclonal antibody from Dako) and 
p27 (SX53G8 monoclonal antibody fom Dako) was 
performed following conventional automated protocols in 
a Autostainer Plus device (Dako).
Gel filtration chromatography
CLL cells were lysed in a 0.5% Triton X-100, 50 
mM Hepes/NaOH pH 7.4, 150 mM NaCl, 1 mM EDTA, 
2,5 mM EGTA, 1 mM dithiothreitol (DTT), 1 mM 
phenylmethylsulphonyl fluoride (PMSF), 10% glycerol 
(w/v). and 1/100 protease inhibitor cocktail (Calbiochem) 
and 2 mg protein samples in a volume of 200 μl were 
applied onto a Superdex 200 10/300 GL column (GE 
Healthcare) equilibrated with chromatography buffer 
(50 mM Hepes pH 7.4, 150 mM NaCl, 1 mM EDTA, 2,5 
mM EGTA, 1 mM DTT, 1 mM PMSF and 10% glycerol) 
and subjected to fast-performance liquid chromatography 
in an ÄKTA apparatus (GE Healthcare) with a flow rate 
of 0.4 ml/min at 4°C. 500 μl fractions were collected 
and subjected to western blot or immunoprecipitation. 
Molecular mass standards for the gel filtration column 
were: apoferritin (443 kDa), catalase (232 kDa), BSA (66 
kDa) and ovalbumin (45 kDa).
Apoptosis assays
MEC1 were transfected with p27 and treated 
with fludarabine (Sigma). Percentage of death cells was 
determined by the Trypan Blue dye exclusion test, by 
annexin V binding detected by flow cytometry (kit of 
Immunostep Research) and by immunobloting with anti-
active caspase 3 (Immunostep Research).
Statistical analysis
Spearman’s rank correlation, Pearson’s correlation, 
t-test and distribution were used to determine correlations, 
dependence and statistical significance. Survival curves 
were analyzed according to the Kaplan and Meier method. 
SPSS Statistics 17.0 and GraphPad Prism software were 
used to different analysis.
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